Based on the professional scientist team and rich development experience, Sanyou Bio explores targets information based on unmet clinical needs and establish an "ad libitum target library" for tumors, autoimmune diseases, cardiovascular diseases, ophthalmic and other diseases. Until now, Sanyou Bio's scientist team has investigated more than 500 targets cumulatively, successfully recommended and developed more than 80 targets covering various disease types and molecular forms. Targets can also be explored based on customer needs to find out the optimal targets for certain disease and the optimal indication layout based on target mechanism.

Sanyou Bio has also collated a complete project approval report for each member of the "target library", and conducted comprehensive research and analysis on target characteristics in terms of target structure, homology, specificity, marketing, clinical progress, patent analysis, etc., and formulated a targeted project development plan, to avoid the whirlpool of "involution" in advance through professional and in-depth target research.

Sanyou Bio has various eukaryotic expression systems such as Expi-CHO transient expression, Expi-293F transient expression and 293F transient expression, which can match with the expression requirements of most proteins. In addition, quality control can be conducted from multiple dimensions such as concentration, purity, molecular weight, stability, safety, charge heterogeneity, sequence variants and structure analysis, binding or blocking biological activity to ensure the quality of antigen antibody proteins.

Through 7-year development, Sanyou Bio has successfully completed the preparation of thousands of proteins, covering various molecular types such as nano-antibodies, human-derived or humanized IgG-type antibodies, cytokines and other types of recombinant proteins, and has accumulated rich experience in protein preparation.

Overexpression cell lines for research are important materials for antibody drug development. Overexpression cell lines are constructed with CHO, HEK293, and various tumor cells by electroporation, chemical transformation and lentiviral infection, and are screened by puromycin, hygromycin, G418, and GS high expression screening systems to obtain stable high-expression cell lines. As of Apr. 2022, hundreds of projects had been completed by Sanyou's cell line construction platform for research, covering the cell lines overexpressing secreted antigens, antibodies, membrane proteins, and transmembrane proteins, and more than 1000 overexpression cell lines had been successfully constructed with CHO, HEK293, Jurkat, and other cells, 90% of which can be stably passaged for 20 PDLs.

Sanyou Bio's molecular discovery integrates animal immunization, fully human or immune-derived B-cell recombinant antibodies, synthetic and semisynthetic antibody libraries construction, phage display antibody libraries, recombinant antibodies mammalian cell expression, automation and high-throughput screening. It covers immune, natural, recombinant, synthetic, and semisynthetic antibody types, suitable for all kinds of antigen cross-screening and difficult targets with high challenge.

Sanyou Bio's "magnetic array high-throughput antibody screening" and rapid protein expression technology covering four key nodes: high-throughput panning, high-throughput screening, high-throughput construction, and high-throughput expression. The seamless connection between "phage display antibody library and mammalian cell protein expression" can help realize automatic, high-throughput, and precise screening. Compared with traditional methods, this platform can accelerate the R&D process by substantially improving the speed of screening and construction. It allows lead molecule discovery within 7 weeks, and allow the analysis of lead molecule early activity and preliminary druggability within 10 weeks, which greatly shorten the time cost of early research and development, and can quickly obtain lead molecules for validation. One-stop panning combined with precise screening has been verified in-depth through nearly 100 projects.

Based on Sanyou Bio's trillion-level fully human/semi-synthetic library, the screening of 16 targets produces the lead molecule at a median of 345 and an average of 317; Using Sanyou trillion humanized single domain antibody library, the screening of 14 targets produces the lead molecule at a median of 606 and an average of 673. It is also possible to obtain a considerable number of lead antibodies for high difficulty target screening and difficult multiple transmembrane protein screening, therefore ensuring sufficient molecules for efficacy screening, improving success rate.

In recent years, antibody drugs represented by immune checkpoint inhibitors have become a hot spot in the development of innovative drug. In this process, the in vitro efficacy evaluation model plays an irreplaceable role, which can greatly accelerate the process of antibody drugs discovery, screening and optimization. Sanyou Bio focused on the research and development of innovative antibody drugs, and it took 7 years to establish a stable, efficient and reliable in vitro efficacy evaluation team. Sanyou Bio systematically developed stable cell efficacy models of tumor surface antigens, suppressive immune checkpoints, co-stimulated immune checkpoints, and other immunomodulators to ensure the high-quality and efficient promotion of candidate antibody cell efficacy screening.

Sanyou Bio in vitro efficacy evaluation covers primary cell isolation, primary cell induction, flow cytometry screening, luciferase reporting system, cell killing, antibody endocytosis detection, phosphorylation detection, cytokine detection, enzyme bioactivity detection, neutrophil chemotaxis, etc. The platform has experience in in vitro efficacy evaluation of 200+ projects, and has established mature cell pharmacodynamic models of 60+ targets, tumor cell lines of 100+ targets, 10+ human primary cells, 40+ SOP guidance. It only takes 6 days to complete all in vitro efficacy evaluations of candidate molecules. Sanyou Bio's one-stop in vitro efficacy evaluation provides scientific, complete and high-quality services for antibody molecular efficacy evaluation.

According to the principle of in vivo affinity maturation, we adopt a variety of mutation strategies, and used phage display technology to construct a large-capacity mutation library to obtain antibodies with significantly improved affinity, covering single point saturation mutation, multi-point sequential mutations, and fixed-point sequential mutations in each CDR. Our SY-FLAM platform (established in 2017) has completed more than 180 affinity maturation projects, and the antibody affinity can be improved up to 100 times.

The in-depth antibody humanization service integrates the technologies of non-human sequence 3D structure simulation and analysis, eukaryotic expression and purification identification, affinity and functional assay, etc. While maintaining the affinity and specificity of the antibody, the degree of humanization of the antibodies can reach more than 95%, and back mutations are less than 6. Since the launch of the service in 2016, SanyouBio has completed more than 200 cases of humanized antibody design, of which more than 40 designed antibodies are in the clinical application stage, and 7 are in the clinical trial stage.

动In vivo efficacy evaluation plays a vital role in basic research and therapeutic drug development. Sanyou Bio is committed to provide you with alternative strains for in vivo efficiency evaluation, corresponding to mechanisms of action, molecular types, mouse strains. A variety of pharmacological indicators such as cytokines, cells distribution and in vivo tumor imaging can be detected via immunohistochemistry, multi-color flow cytometry, and in vivo imaging.

By September 2022, we have successfully developed 80+ tumor models, covering major tumors, hematoma, autoimmunity (asthma), cardiovascular disease. And we have successfully completed efficacy evaluation of a series of targets such as TNFR2 and CD39, and accumulated extensive project experience for different molecular types.

Based on "super-trillion phage display antibody library" and "integrated intelligent R & D platform for preclinical innovative antibody drugs", Sanyou Bio provides a one-stop R & D service from target to PCC and delivers preclinical candidate molecules (PCC) with favorable druggability potential.

As of September 2022, Sanyou Bio has accumulated nearly 100 projects’ experiences in PCC drug development, covering various antibody forms and indications, and are expected to complete 70+ PCC projects in 2022.

PCC molecular forms include monoclonal antibodies, bispecific antibodies, trispecific antibodies, and ADCs. The indications for the targets under development focus on oncology, autoimmune, infection, ophthalmology, and metabolism aspects.

After 7-years continuous innovation, Sanyou Bio's technical teams formed unique technical barriers and core competence through collaborative investigation on project approval, integrated raw material solution, super-trillion phage display antibody library, one-stop in vitro efficacy evaluation, structure simulation + antibody engineering, and animal model-based efficacy, which is a solid support for the integrated intelligent R&D service of innovative drugs.